Research and development for clinical studies in the blueprint medtech. Ordering period: 09/01/2023 - 8/31/2028. (bpmt) initiative.
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- 75N95023D00011
- Awardee
-
PPD Development LP UEI ZANENSW6C665
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Task orders
- 1 $324,420 obligated
Award facts
- Opportunity
-
- Research and Development for Clinical Studies in the Blueprint MedTech (BPMT) Pre-Solicitation · 75N95022R00050 · Posted Apr 18, 2022
- Combined order value
- $324,420 Current and potential, with all options
- Last date to order 63% complete
- IDV ceiling 1% used
- $49,900,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
The National Institute on Drug Abuse awarded a single-award indefinite delivery contract to PPD Development LP on September 1, 2023, with a $49.9 million ceiling through August 31, 2028, to provide research and development support for clinical studies under the Blueprint MedTech initiative. The contract is unrestricted (no set-aside). Work is performed at PPD Development LP's facility in Cape Fear, North Carolina. The originating solicitation, posted in April 2022, sought clinical research support services including biocompatibility studies, GLP animal testing, sterilization and shelf-life testing, protocol development, and staff training to support an estimated 20 medical device studies over the five-year period. The contract structure allows task orders for distinct studies at cost reimbursement and/or fixed-price rates. One task order has been issued under this vehicle: Task Order 02, awarded June 17, 2024, valued at $324,420, for clinical study protocol development running through June 16, 2029, on a firm fixed-price basis. PPD Development LP, a subsidiary of Thermo Fisher Scientific, is a clinical research organization with extensive experience in clinical trial management, regulatory affairs support, and medical device development services to federal agencies.
Task orders
| Task order | Ordering agency | Obligated | Awarded |
|---|---|---|---|
| Research and development for clinical studies in the blueprint medtech. Clinical study protocol development. Task order… | National Institute on Drug Abuse (NIH) | $324,420 |
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N95023D00011?
75N95023D00011 was awarded to PPD Development LP by National Institute on Drug Abuse (National Institutes of Health) on September 1, 2023.
How much is contract 75N95023D00011 worth?
Orders under 75N95023D00011 have obligated $324,420. 75N95023D00011's own ceiling is $49,900,000.
How many orders have been placed under contract 75N95023D00011?
1 order has been placed under 75N95023D00011, the latest on June 17, 2024.
Who can order from contract 75N95023D00011?
75N95023D00011 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract 75N95023D00011 competed?
The extent of competition for 75N95023D00011 was full and open competition. The government received 2 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV